Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.21
+0.20000.80%
Post-market: 25.210.00000.00%19:30 EDT
Volume:469.79K
Turnover:11.83M
Market Cap:1.00B
PE:71.67
High:25.66
Open:25.04
Low:24.66
Close:25.01
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.87
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.50
PE(LYR):159.73

Loading ...

Oppenheimer Initiates Pacira Biosciences at Outperform With $32 Price Target

MT Newswires Live
·
Sep 23

Pacira BioSciences Price Target Announced at $32.00/Share by Oppenheimer

Dow Jones
·
Sep 23

Pacira BioSciences Price Target Announced at $28.00/Share by Leerink Partners

Dow Jones
·
Sep 09

Pacira Grants Inducement Equity Awards to New Hires, Including Options Priced at $26.58 Per Share

Reuters
·
Sep 09

Pacira Biosciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 09

Leerink Partners Initiates Coverage on Pacira Biosciences With Market Perform Rating, $28 Price Target

MT Newswires Live
·
Sep 09

Pacira initiated with a Market Perform at Leerink

TIPRANKS
·
Sep 09

Pacira BioSciences CMO Jonathan Slonin Sells 3,040 Shares for $70,619.20

Reuters
·
Aug 19

Pacira Biosciences, Inc. : Truist Securities Reinstates Coverage with Buy Rating; Price Target $30

THOMSON REUTERS
·
Aug 17

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Simply Wall St.
·
Aug 10

Pacira Grants Inducement Equity Awards to New Hires, Including Options Priced at $27.62/share

Reuters
·
Aug 07

Press Release: Pacira BioSciences Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dow Jones
·
Aug 07

Pacira Publishes Positive Two-Year Phase 1 Data for PCRX-201 Gene Therapy in Knee Osteoarthritis

Reuters
·
Aug 06

Pacira BioSciences is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Aug 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 06

RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating

MT Newswires Live
·
Aug 05

Pacira Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Pacira Q2 FY26 Returns to GAAP Profit of USD 4.7 Million; Revenue Rises 6% to USD 192.4 Million

Reuters
·
Aug 05

Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate

Benzinga Earnings
·
Aug 05

Pacira Biosciences Q2 Revenue USD 192.4 Million Vs. IBES Estimate USD 190.8 Million

Reuters
·
Aug 05